Indaptus Therapeutics Inc (INDP) is not a strong buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with declining net income and EPS, and there are no significant positive catalysts or trading signals to suggest immediate growth potential. Additionally, there is no recent news, analyst ratings, or congress trading data to support a bullish outlook.

Technical Analysis

The MACD is positively expanding, indicating a slight bullish momentum. RSI is neutral at 64.388, and moving averages are converging, showing no clear trend. Key resistance levels are at 2.113 and 2.245, while support levels are at 1.685 and 1.553.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Weak financial performance with declining net income (-3.06% YoY) and EPS (-67.04% YoY). No significant trading trends or positive sentiment indicators.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$2,975,117 (-3.06% YoY), and EPS fell sharply to -2.98 (-67.04% YoY). Gross margin remained at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast INDP stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.063

Low

Averages

High